Abstract
BackgroundRituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen expressed at the B cell surface. It was first used for the treatment of non-Hodgkin's lymphoma and then...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
